Int J Mol Sci. 2025 Dec 5;26(24):11769. doi: 10.3390/ijms262411769.

ABSTRACT

Hypoxia-inducible factor-1 (HIF-1) enhances cancer cell survival in hypoxic conditions. The ketogenic diet (KGD), characterized by low-carbohydrate and high-fat intake, has been widely used for epilepsy treatment and reported to have antitumor potential. However, its impact on hypoxic cancer cells remains poorly understood. This study examined the effects of combining the HIF-1α inhibitor YC-1 with the KD formula KetoCal® on hypoxic hepatocellular carcinoma (HCC) cells. In vitro, HIF-1α knockdown (KD) and scramble control (SC) Hep3B and HepG2 cells were treated with palmitic acid (PA) and/or β-hydroxybutyrate (BOH) to mimic the KGD environment. PA significantly induced cell death and reactive oxygen species (ROS) in hypoxic KD cells, and this effect was further enhanced by BOH. Gene expression analysis indicated that HIF-1 suppresses fatty acid oxidation (FAO) and ketolysis under hypoxia. In vivo, Hep3B cells were implanted into mice fed KetoCal® with or without YC-1. KetoCal® elevated serum BOH and free fatty acids (FFAs), suppressed tumor growth, and increased intra-tumoral acetyl-CoA, ROS, and apoptosis in YC-1-treated tumors. These findings suggest that YC-1 combined with KetoCal® reactivates FAO and ketolysis, promoting acetyl-CoA accumulation and lethal ROS production in hypoxic HCC. This strategy may offer a novel preclinical model for targeting hypoxic tumors.

PMID:41465202 | DOI:10.3390/ijms262411769

From ketogenic via this RSS feed